US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

LNTH•2026-08-14

FDA approval for Alzheimer's brain scans

The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.

US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

FDA approval for Alzheimer's brain scans

Related News

US July retail sales data

FG Nexus declares $0.5 quarterly dividend on 8% Series A preferred stock

U.S. Physical Therapy names Nchacha Etta CFO effective Sept. 1

Quoin net loss widens 45.32% to $5.4 million in Q2 FY26

Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trial